Company overview
Inpart provides an end-to-end platform for biopharma R&D teams to discover, evaluate, and manage partnerships with academia, startups, and research institutes. Its tools like Deal CRM and Connect matchmaking streamline opportunity tracking, dealmaking, and scouting campaigns. Used by over 6,500 companies including 45 of the top 50 global pharma firms, it accelerates innovation pipelines through data unification and expert curation.
Inpart is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include biopharma partnering, r&d scouting, academic collaboration, deal crm, innovation platform.
Structured facts
- Website
- https://www.inpart.io
- Markets served
- United States & Americas
- Keywords
- biopharma partnering, r&d scouting, academic collaboration, deal crm, innovation platform
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What capabilities does Inpart offer for biopharma R&D partnering?
- Inpart offers Deal CRM for centralizing partnering data and opportunity tracking, Connect for matchmaking with academic and startup technologies, and Campaigns for targeted scouting of proposals from global research networks.
- What industries and geographies does Inpart serve?
- Inpart serves biopharma, scientific, and academic sectors globally, connecting over 6,500 companies including top pharma firms with more than 200 leading universities and a network of startups and SMEs worldwide.
- How does Inpart ensure regulatory and data security compliance?
- Inpart provides secure, integrated platforms with structured data intake, intelligent syncing, and collaboration tools designed for biopharma, used by top R&D-intensive firms without mention of specific regulatory certifications in available details.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
